Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Sharfman

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Pediatric Blood & Cancer|October 30, 2004
Pediatric melanomaWilliam Sharfman, Julie Lange, Charles M Balch
Annals of Surgical Oncology|May 22, 2010
Improvements in the staging of cutaneous squamous-cell carcinoma in the 7th edition of the AJCC Cancer Staging ManualThomas Lardaro, Sofia M Shea, William Sharfman, et al.
Gastroenterology|October 23, 2020
Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor ColitisShrinivas Bishu, Joanna Melia, William Sharfman, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 15, 2017
Two Cases of Sinusitis Induced by Immune Checkpoint InhibitionEric Dein, William Sharfman, Jean Kim, et al.
Cancer|January 29, 2010
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanomaPeter Hersey, Jeffrey Sosman, Steven O'Day, et al.
Cancer|May 12, 2005
A phase II study of bortezomib in the treatment of metastatic malignant melanomaSvetomir N Markovic, Susan M Geyer, Fitzroy Dawkins, et al.
The Oncologist|May 13, 2017
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of EncephalitisJames Larkin, Bartosz Chmielowski, Christopher D Lao, et al.
International Journal of Radiation Oncology, Biology, Physics|February 28, 2018
Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell CarcinomaLinda Chen, Jacqueline Douglass, Lawrence Kleinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2025
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II StudyShailender Bhatia, Suzanne L Topalian, William Sharfman, et al.
Cancer Medicine|July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation statusBenjamin Izar, William Sharfman, F Stephen Hodi, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Pediatric Blood & Cancer|October 30, 2004
Pediatric melanomaWilliam Sharfman, Julie Lange, Charles M Balch
Annals of Surgical Oncology|May 22, 2010
Improvements in the staging of cutaneous squamous-cell carcinoma in the 7th edition of the AJCC Cancer Staging ManualThomas Lardaro, Sofia M Shea, William Sharfman, et al.
Gastroenterology|October 23, 2020
Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor ColitisShrinivas Bishu, Joanna Melia, William Sharfman, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 15, 2017
Two Cases of Sinusitis Induced by Immune Checkpoint InhibitionEric Dein, William Sharfman, Jean Kim, et al.
Cancer|January 29, 2010
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanomaPeter Hersey, Jeffrey Sosman, Steven O'Day, et al.
Cancer|May 12, 2005
A phase II study of bortezomib in the treatment of metastatic malignant melanomaSvetomir N Markovic, Susan M Geyer, Fitzroy Dawkins, et al.
The Oncologist|May 13, 2017
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of EncephalitisJames Larkin, Bartosz Chmielowski, Christopher D Lao, et al.
International Journal of Radiation Oncology, Biology, Physics|February 28, 2018
Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell CarcinomaLinda Chen, Jacqueline Douglass, Lawrence Kleinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2025
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II StudyShailender Bhatia, Suzanne L Topalian, William Sharfman, et al.
Cancer Medicine|July 19, 2017
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation statusBenjamin Izar, William Sharfman, F Stephen Hodi, et al.
Pageof 2